Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement

Haemophilia

Volumn 23, Issue 3, 2017, Pages e170-e179

  Iorio, A ^a   Iserman, E ^a   Blanchette, V ^b   Dolan, G ^c   Escuriola Ettingshausen, C ^d   Hermans, C ^e   Negrier, C ^f   Oldenburg, J ^g   Reininger, A ^h   Rodriguez Merchan, C ⁱ   Spannagl, M ^j   Valentino, L A ^k   Young, G ^l   Steinitz Trost, K N ^h   Gringeri, A ^h  

^a MCMASTER UNIVERSITY   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d HZRM   (Germany)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f UNIVERSITÉ LYON 1   (France)

^g UNIVERSITY HOSPITAL BONN   (Germany)

^h Baxalta Innovations GmbH   (Austria)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^k RUSH UNIVERSITY   (United States)

^l UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

haemophilia; individualization; personalized; prophylaxis; tailoring

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ARTICLE; CONSENSUS; DELPHI STUDY; EXPERT SYSTEM; HEMOPHILIA; HUMAN; PERSONALIZED MEDICINE; PLASMA FACTOR; PRIORITY JOURNAL; PROPHYLAXIS; BLOOD; EXPERT WITNESS; HEMOPHILIA A; METABOLISM; QUESTIONNAIRE;

CONSENSUS; DELPHI TECHNIQUE; EXPERT TESTIMONY; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HUMANS; PRECISION MEDICINE; SURVEYS AND QUESTIONNAIRES;

EID: 85016641026     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13215     Document Type: Article

References (21)

1. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535–44.
2. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2011; 9: CD003429.
3. Gringeri a, Lundin B, Mackensen S V, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700–10.
4. Valentino L a, Mamonov V, Hellmann a et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359–67.
5. Manco-Johnson MJ, Kempton CL, Reding MT et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11: 1119–27.
6. Collins PW, Blanchette VS, Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413–20.
7. Collins PW, Björkman S, Fischer K et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269–75.
8. Valentino LA, Pipe SW, Collins PW et al. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis. Haemophilia 2016; 22: 514–520.
9. Custer RL, Scarcella JA, Stewart BR. The Modified Delphi Technique - A Rotational Modification. Digital Library and Archives of the Virginia Tech University Libraries.
10. Sinha IP, Smyth RL, Williamson PR. Using the Delphi technique to determine which outcomes to measure in clinical trials: Recommendations for the future based on a systematic review of existing studies. PLoS Med 2011; 8: e1000393.
11. Hsu C, Sandford B. The delphi technique: making sense of consensus. Pract Assess Res Eval 2007; 12: 1–8.
12. Feldman BM, Pai M, Rivard GE et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228–36.
13. Hilliard P, Zourikian N, Blanchette V et al. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. J Thromb Haemost 2013; 11: 460–6.
14. Risebrough N, Oh P, Blanchette V, Curtin J, Hitzler J, Feldman BM. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia 2008; 14: 743–52.
15. Wu R, Luke K-H, Poon M-C et al. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Haemophilia 2011; 17: 70–4.
16. Gringeri A, Doralt J, Valentino LA, Crea R, Reininger AJ. An innovative outcome-based care and procurement model of hemophilia management. Expert Rev Pharmacoecon Outcomes Res 2016; 16: 337–45.
17. McEneny-King A, Iorio A, Foster G, Edginton AN. The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A. Expert Opin Drug Metab Toxicol 2016; 12: 1313–21.
18. Iorio A, McEneny-King A, Foster G, Edginton AN. What is the role for population pharmacokinetics in hemophilia? Int J Pharmacokinet 2017; 2: 1–22.
19. ® in patients with severe haemophilia A without inhibitors. Haemophilia 2017; 23: e50–4.
20. Iorio A, Keepanasseril A, Foster G et al. Development of a web accessible population pharmacokinetic service - Hemophilia (WAPPS-Hemo): Study Protocol. JMIR RP 2016; 5: e239.
21. McEneny-King A, Foster G, Iorio A, Edginton AN. Data analysis protocol for the development and evaluation of population pharmacokinetic models for incorporation into the web-accessible population pharmacokinetic service - Hemophilia (WAPPS-Hemo). JMIR Res Protoc 2016; 5: e232.